A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia

NCT01292603 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphocytic Leukemia, Chronic

Interventions

DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: rituximab [MabThera]
DRUG: rituximab [MabThera]
DRUG: rituximab [MabThera]

Sponsor

Hoffmann-La Roche